HIGHLIGHTS
- who: Yan-yan Zhu from the The Open University, United Kingdom have published the article: Case Report: Torsade de Pointes Induced by the Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Osimertinib Combined With Litsea Cubeba, in the Journal: (JOURNAL) of January/02,/2022
SUMMARY
Osimertinib is an oral, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), recommended as a first-line treatment for EGFR-mutated advanced or metastasis non-small cell lung cancer (NSCLC). Since vascular and cardiac potassium channels are regulated largely by EGFR tyrosine kinase . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.